Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. by West, N, Hegazy, A, Owens, B, Bullers, S, Linggi, B, Buonocore, S, Coccia, M, Görtz, D, This, S, Stockenhuber, K, Pott, J, Friedrich, M, Ryzhakov, G, Baribaud, F, Brodmerkel, C, Cieluch, C, Rahman, N, Müller-Newen, G, Owens, R, Kühl, A, Maloy, K, Plevy, S, Oxford IBD Cohort Investigators, Keshav, S, Travis, S, Powrie, F

Variants in TRIM22 that affect NOD2 signaling are associated with very early onset inflammatory bowel disease by Li, Q, Lee, C, Peters, L, Mastropaolo, L, Thoeni, C, Elkadri, A, Schwerd, T, Zhu, J, Zhang, B, Zhao, Y, Hao, K, Dinarzo, A, Hoffman, G, Kidd, B, Murchie, R, Al Adham, Z, Guo, C, Kotlarz, D, Cutz, E, Walters, T, Shouval, D, Curran, M, Dobrin, R, Brodmerkel, C, Snapper, S, Klein, C, Brumell, J, Hu, M, Nanan, R, Snanter-Nanan, B, Wong, M, Le Deist, F, Haddad, E, Roifman, C, Deslandres, C, Griffiths, A, Gaskin, K, Uhlig, H, Schadt, E, Muise, A